A Phase 2 Study of Cediranib in Combination With Olaparib in Advanced Solid Tumors
Phase of Trial: Phase II
Latest Information Update: 05 Aug 2018
At a glance
- Drugs Cediranib (Primary) ; Olaparib (Primary)
- Indications Adenocarcinoma; Advanced breast cancer; Non-small cell lung cancer; Pancreatic cancer; Small cell lung cancer
- Focus Therapeutic Use
- 04 Jun 2018 Planned primary completion date changed from 31 May 2018 to 30 Jun 2019.
- 10 Jun 2017 Biomarkers information updated
- 30 Jun 2016 Planned number of patients changed from 121 to 126.